86 related articles for article (PubMed ID: 29253683)
1. A standardized stepwise drug treatment algorithm for depression reduces direct treatment costs in depressed inpatients - Results from the German Algorithm Project (GAP3).
Ricken R; Wiethoff K; Reinhold T; Stamm TJ; Baghai TC; Fisher R; Seemüller F; Brieger P; Cordes J; Laux G; Hauth I; Möller HJ; Heinz A; Bauer M; Adli M
J Affect Disord; 2018 Mar; 228():173-177. PubMed ID: 29253683
[TBL] [Abstract][Full Text] [Related]
2. Algorithm-guided treatment of depression reduces treatment costs--results from the randomized controlled German Algorithm Project (GAPII).
Ricken R; Wiethoff K; Reinhold T; Schietsch K; Stamm T; Kiermeir J; Neu P; Heinz A; Bauer M; Adli M
J Affect Disord; 2011 Nov; 134(1-3):249-56. PubMed ID: 21757237
[TBL] [Abstract][Full Text] [Related]
3. How Effective Is Algorithm-Guided Treatment for Depressed Inpatients? Results from the Randomized Controlled Multicenter German Algorithm Project 3 Trial.
Adli M; Wiethoff K; Baghai TC; Fisher R; Seemüller F; Laakmann G; Brieger P; Cordes J; Malevani J; Laux G; Hauth I; Möller HJ; Kronmüller KT; Smolka MN; Schlattmann P; Berger M; Ricken R; Stamm TJ; Heinz A; Bauer M
Int J Neuropsychopharmacol; 2017 Sep; 20(9):721-730. PubMed ID: 28645191
[TBL] [Abstract][Full Text] [Related]
4. Clinical results for patients with major depressive disorder in the Texas Medication Algorithm Project.
Trivedi MH; Rush AJ; Crismon ML; Kashner TM; Toprac MG; Carmody TJ; Key T; Biggs MM; Shores-Wilson K; Witte B; Suppes T; Miller AL; Altshuler KZ; Shon SP
Arch Gen Psychiatry; 2004 Jul; 61(7):669-80. PubMed ID: 15237079
[TBL] [Abstract][Full Text] [Related]
5. Texas Medication Algorithm Project, phase 3 (TMAP-3): rationale and study design.
Rush AJ; Crismon ML; Kashner TM; Toprac MG; Carmody TJ; Trivedi MH; Suppes T; Miller AL; Biggs MM; Shores-Wilson K; Witte BP; Shon SP; Rago WV; Altshuler KZ;
J Clin Psychiatry; 2003 Apr; 64(4):357-69. PubMed ID: 12716235
[TBL] [Abstract][Full Text] [Related]
6. Texas Medication Algorithm Project, phase 3 (TMAP-3): clinical results for patients with a history of mania.
Suppes T; Rush AJ; Dennehy EB; Crismon ML; Kashner TM; Toprac MG; Carmody TJ; Brown ES; Biggs MM; Shores-Wilson K; Witte BP; Trivedi MH; Miller AL; Altshuler KZ; Shon SP;
J Clin Psychiatry; 2003 Apr; 64(4):370-82. PubMed ID: 12716236
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of an algorithm-guided treatment compared with treatment as usual: a randomized, controlled study of inpatients with depression.
Bauer M; Pfennig A; Linden M; Smolka MN; Neu P; Adli M
J Clin Psychopharmacol; 2009 Aug; 29(4):327-33. PubMed ID: 19593170
[TBL] [Abstract][Full Text] [Related]
8. Escitalopram: a pharmacoeconomic review of its use in depression.
Croom KF; Plosker GL
Pharmacoeconomics; 2003; 21(16):1185-209. PubMed ID: 14594439
[TBL] [Abstract][Full Text] [Related]
9. The incremental cost effectiveness of in-patient versus out-patient rehabilitation after total hip arthroplasty - results of a pilot investigation.
Krummenauer F; Günther KP; Witzlebf WC
Eur J Med Res; 2008 Jun; 13(6):267-74. PubMed ID: 18558552
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of usual general practitioner care with or without antidepressant medication for patients with minor or mild-major depression.
Bosmans JE; Hermens ML; de Bruijne MC; van Hout HP; Terluin B; Bouter LM; Stalman WA; van Tulder MW
J Affect Disord; 2008 Nov; 111(1):106-12. PubMed ID: 18342952
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness and feasibility of a standardized stepwise drug treatment regimen algorithm for inpatients with depressive disorders: results of a 2-year observational algorithm study.
Adli M; Berghöfer A; Linden M; Helmchen H; Müller-Oerlinghausen B; Mackert A; Stamm T; Bauer M
J Clin Psychiatry; 2002 Sep; 63(9):782-90. PubMed ID: 12363118
[TBL] [Abstract][Full Text] [Related]
12. The Texas medication algorithm project: clinical results for schizophrenia.
Miller AL; Crismon ML; Rush AJ; Chiles J; Kashner TM; Toprac M; Carmody T; Biggs M; Shores-Wilson K; Chiles J; Witte B; Bow-Thomas C; Velligan DI; Trivedi M; Suppes T; Shon S
Schizophr Bull; 2004; 30(3):627-47. PubMed ID: 15631256
[TBL] [Abstract][Full Text] [Related]
13. [The social cost of depression in the city of Sabadell (Barcelona, Spain) (2007-2008)].
Pamias Massana M; Crespo Palomo C; Gisbert Gelonch R; Palao Vidal DJ
Gac Sanit; 2012; 26(2):153-8. PubMed ID: 22055213
[TBL] [Abstract][Full Text] [Related]
14. Challenging sequential approach to treatment resistant depression: cost-utility analysis based on the Sequenced Treatment Alternatives to Relieve Depression (STAR(⁎)D) trial.
Olgiati P; Bajo E; Bigelli M; Montgomery S; Serretti A;
Eur Neuropsychopharmacol; 2013 Dec; 23(12):1739-46. PubMed ID: 24075716
[TBL] [Abstract][Full Text] [Related]
15. The effect of severity of depressive disorder on economic burden in a university hospital in Singapore.
Ho RC; Mak KK; Chua AN; Ho CS; Mak A
Expert Rev Pharmacoecon Outcomes Res; 2013 Aug; 13(4):549-59. PubMed ID: 23977979
[TBL] [Abstract][Full Text] [Related]
16. Cost of depression in Europe.
Sobocki P; Jönsson B; Angst J; Rehnberg C
J Ment Health Policy Econ; 2006 Jun; 9(2):87-98. PubMed ID: 17007486
[TBL] [Abstract][Full Text] [Related]
17. [Does the hospital cost of care differ for inflammatory bowel disease patients with or without gastrointestinal infections? A case-control study].
Schmidt C; Köhler F; Kräplin T; Hartmann M; Lerch MM; Stallmach A
Z Gastroenterol; 2014 Jul; 52(7):643-8. PubMed ID: 25026005
[TBL] [Abstract][Full Text] [Related]
18. The mission is remission: health economic consequences of achieving full remission with antidepressant treatment for depression.
Sobocki P; Ekman M; Agren H; Runeson B; Jönsson B
Int J Clin Pract; 2006 Jul; 60(7):791-8. PubMed ID: 16846399
[TBL] [Abstract][Full Text] [Related]
19. Modelling the cost effectiveness of antidepressant treatment in primary care.
Revicki DA; Brown RE; Palmer W; Bakish D; Rosser WW; Anton SF; Feeny D
Pharmacoeconomics; 1995 Dec; 8(6):524-40. PubMed ID: 10160081
[TBL] [Abstract][Full Text] [Related]
20. Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide in rheumatoid arthritis in Germany: I. Selected DMARDs and patient-related costs.
Schädlich PK; Zeidler H; Zink A; Gromnica-Ihle E; Schneider M; Straub C; Brecht JG; Huppertz E
Pharmacoeconomics; 2005; 23(4):377-93. PubMed ID: 15853437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
